Price
$4.76+2.15%Social Signal Score
Analyst Ratings
9 analystsRevenue
$45.38M+303.13%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John T. Treace
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 450
- Beta
- 1.41
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -0.00
Financials
Revenue
$45.38M+303.1%Net Income
$-15.87MEBITDA
$-12.42MFree Cash Flow
$-6.90MEPS (diluted)
$-0.24Shares Outstanding (diluted)
65.05M+48.2%Operating Expenses
$50.56MCash & Debt
$45.62MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $212.69M | $-59.00M | $-0.93 |
| 2024 | $209.36M | $-55.74M | $-0.90 |
| 2023 | $187.12M | $-49.53M | $-0.81 |
| 2022 | $141.84M | $-42.81M | $-0.77 |
| 2021 | $94.42M | $-20.55M | $-0.38 |
| 2020 | $57.37M | $-3.67M | $-0.08 |
| 2019 | $39.42M | $-4.26M | $-0.10 |
Valuation
TMCIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·18d ago·Neutral
…tive Outcomes of the Lapiplasty® Procedure PONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle conditions, today announced the presentation of the results from three clinical studies at the American Orthopaedic Foot & Ankle Society (“AOFAS”) Annual Meeting in Seattle, Washington. The presentations includ…
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting New product offerings extend bunion market leadership and accelerate penetration into new foot & ankle market adjacencies New product offerings extend bunion market leadership and accelerate penetration into new foot & ankle market adjacencies
View source ↗ - Newsseekingalpha.com·59d ago·Positive
Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.26 per share
Typical surprise +19.4% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 7$-0.24 vs $-0.30beat
- Fri, May 8$-0.28 vs $-0.31beat
- Fri, Feb 27$-0.12 vs $-0.15beat
- Thu, Nov 6$-0.26 vs $-0.28beat
- Thu, Aug 7$-0.28 vs $-0.29beat
- Thu, May 8$-0.25 vs $-0.31beat
Estimates and results for TMCI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TMCI officers and directors.
- Bought
- $2.0m
- Sold
- $398k
15 trades
1 trade
- Treace John T.boughtdirector, 10 percent owner, officer: Chief Executive Officer·11,000 @ $4.34·$48k·Aug 24, 2026·filing
- Treace John T.bought
- Treace John T.boughtdirector, 10 percent owner, officer: Chief Executive Officer·39,944 @ $4.44·$177k·Aug 20, 2026·filing
- Treace John T.bought
- Treace John T.boughtdirector, 10 percent owner, officer: Chief Executive Officer·22,887 @ $4.04·$93k·Jun 11, 2026·filing
- Treace John T.boughtdirector, 10 percent owner, officer: Chief Executive Officer·14,715 @ $4.02·$59k·Jun 10, 2026·filing
- Treace John T.boughtdirector, 10 percent owner, officer: Chief Executive Officer·29,430 @ $4.02·$118k·Jun 10, 2026·filing
- Treace John T.boughtdirector, 10 percent owner, officer: Chief Executive Officer·50,000 @ $3.56·$178k·Jun 1, 2026·filing
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TMCI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.